NCT02179918 - A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Advanced Solid Tumors

Interventions

DRUG

PF-05082566

Starting dose of 0.45 mg/kg q3wks IV, dose escalation

DRUG

MK-3475

2 mg/kg q3wks, IV

Trial Locations (9)

South Texas Accelerated Research Therapeutics, LLC, San Antonio

Research Administration Office, Los Angeles

Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles

UCLA Hematology-Oncology Clinic, Los Angeles

UCLA Oncology Center, Los Angeles

Seattle Cancer Care Alliance, Seattle

University of Washington Medical Center, Seattle

Smilow Cancer Center at Yale-New Haven Hospital, New Haven

Smilow Cancer Hospital at Yale-New Haven, New Haven